Evolocumab for cholesterol: After one year, patients on new drug fare better than standard therapy
Monday, March 16, 2015 - 10:30
in Health & Medicine
Patients taking evolocumab -- an investigational therapy previously shown to dramatically lower 'bad' cholesterol -- were half as likely to die, suffer a heart attack or stroke, be hospitalized or need a procedure to open blocked arteries compared with those who received standard care, according to new research.